PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-1.89%
Both yoy net incomes decline, with AGEN at -32.81%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
6.88%
Some D&A expansion while AGEN is negative at -0.51%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
-2.69%
Both cut yoy SBC, with AGEN at -118.00%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-183.61%
Both reduce yoy usage, with AGEN at -460.17%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-219.11%
Both negative yoy AP, with AGEN at -346.35%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
200.00%
Some yoy usage while AGEN is negative at -511.48%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
No Data
No Data available this quarter, please select a different quarter.
-50.21%
Both yoy CFO lines are negative, with AGEN at -39.58%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
33.33%
We repay more while AGEN is negative at -2.62%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
-53.76%
Negative yoy issuance while AGEN is 240.50%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.